StockTipsArenaBeta

SELL Sun Pharmaceutical Industries Ltd. — Rajesh Palviya, Axis Securities

SELLSun Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries share price target & all analyst calls

byRajesh Palviya, Axis SecuritiesHorizon: 1–3 months5 Oct 2026via CNBC Awaaz.

Entry₹1,775Inferred
Target₹1,720
Total upside +3.10%
Stop loss₹1,800-1.41% risk
CMP₹1,804.1Just now
Active-1.64%+4.66%upside left 3 mo left
Follow Rajesh Palviya for new calls(35% target hit, 23 closed calls)Get alertsWatch SUNPHARMA for new buy/sell callsGet alertsSee 5 other Short-term calls on SUNPHARMASee 47 other Short-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this SELL call — facts from public sources, machine-classified. Not investment advice.

As of 6 Oct, 4:18 pm IST
1 supporting1 neutral6 opposing
Supports the SELL call (1)

Sun Pharma subsidiaries settle US generic drug pricing antitrust case for confidential amount

NewsCnbc-Tv18·11 Sept · 3w ago

(opens in new tab)
Neutral / worth noting (1)

Sun Pharmaceutical Industries Ltd has been assigned international issuer credit ratings by Moody's Ratings (Baa1, Stable Outlook) and S&P Global Ratings (BBB+, Stable Outlook). These ratings are inves

BSE · Company Update·8 Sept · 4w ago

(opens in new tab)
Weighs against the SELL call (6)

MACD above its signal line — bullish momentum

Technicals · macd·6 Oct · today

Sun Pharma to acquire Innovcare Lifesciences for ₹271.2 crore

NewsGoogle News·4 Oct · 2d ago

(opens in new tab)

13 advisors have active long-term BUY calls on this stock, with 2 issued in the last 14 days

Advisor consensus · adjacent horizon·29 Sept · 1w ago

Sun Pharmaceutical has entered into a licensing agreement for lerodalcibep, a novel drug candidate, expanding its specialty portfolio.

BSE · Company Update·28 Sept · 1w ago

(opens in new tab)

5 other SEBI-registered advisors have active short-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · same horizon·23 Sept · 2w ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Sun Pharmaceutical Industries

All analyst calls on Sun Pharmaceutical Industries

More from Rajesh Palviya, Axis Securities

Every call and its outcome